Independent : reported that Teenage boys face long wait for HPV vaccine

The powerful HPV vaccine won't be rolled out to teenage boys until September next year at the earliest, the Sunday Independent has confirmed. Now the authorities are re-examining the possibility of protecting teenage boys against HPV. It comes as a new study has found that teenage girls who receive the HPV vaccine are not at risk of chronic fatigue syndrome. However, new research on more than 175,000 Norwegian girls showed that there is no increased risk for those who receive the vaccine. The Norwegian institute of public health scientists discovered unvaccinated girls faced the same risk of developing chronic fatigue syndrome.

HPV vaccine doesn't cause chronic fatigue syndrome

Teenage girls who have the controversial HPV Vaccine are not at risk of chronic fatigue syndrome, a major study confirms. Study author Berit Feiring said: 'This is a major study where we have investigated the association between HPV vaccination and chronic fatigue syndrome. During the study period, just 407 girls who had been administered the vaccine were diagnosed with chronic fatigue syndrome. Another sporty 13-year-old suffered an alleged reaction to the HPV vaccine that left her reliant on a wheelchair. For the study published in the journal Vaccine, researchers tracked the health records of 176,453 girls who had the HPV vaccine.

Barriers to HPV vaccine uptake identified, suggestions to overcome such obstacles offered

"Factors influencing nurse practitioner provider recommendations of the HPV vaccine: A pilot study survey." Presented at: American Association of Nurse Practitioners National Conference; Jun. The researchers found that barriers that may inhibit the HPV vaccine from being administered included parents' concerns about their child's safety, parents' own personal belief system, and that some were not aware of a HPV vaccine for boys. PHILADELPHIA — HPV vaccine rates in 2015 were below the Healthy People 2020 target of 80%, suggesting an opportunity for nurse practitioners to help improve these numbers, according to a presenter here at the annual meeting of the American Association of Nurse Practitioners. Though the HPV vaccine provides 100% protection against HPV-related cancers when given before its coital debut, the vaccine series was completed in only 41.9% in females and 28.1% of males in 2015, researchers added. To ascertain some of the barriers and facilitators that could be contributing to the low numbers, Cassidy and colleagues analyzed 86 survey responses from nurse practitioners in southwestern Pennsylvania.


collected by :Lucy William

To follow all the new news about Health care